Poolbeg Pharma (POLB) Ord Shares
- Add to watchlist
- Create an alert
- This stock can be held in a
n/a
n/a
15.70p
£35.50 million
7.10p
n/a
7.10p
n/a
0.00p (0.00%) Previous:
0.00p
n/a
n/a
30,000
Performance
1 week 1W | 3.4% | 1 year 1Y | 21.55% |
---|---|---|---|
1 month 1M | 21.11% | 2 years 2Y | 18.86% |
3 months 3M | 36.89% | 3 years 3Y | 19.77% |
6 months 6M | 45.59% | 5 years 5Y | n/a |
Performance figures are based on the previous close price. Past performance is not an indication of future performance.
Fundamental data
Year ending: | 31/12/2023 | 31/12/2022 |
---|---|---|
Revenue (£m) | n/a | n/a |
Profit before tax (£m) | (4.50) | (4.78) |
Adjusted EPS (p): | (0.79) | (0.94) |
P/E ratio | n/a | n/a |
PEG | n/a | n/a |
EPS growth (%) | n/a | n/a |
Values are quoted in the stock's local currency: British pound
All fundamental dataDividend information for this stock is not available.
Dividend information for this stock is not available.
Ready to invest?
Important Documents
There are no documents available for this stock.
-
Poolbeg Pharma granted new US patent
20 November 2024 13:56
-
Poolbeg agrees 12-month option over potential Behcet's treatment
30 April 2024 16:43
-
Poolbeg Pharma to be granted US patent
20 March 2024 11:10
-
POLB 001 Patent Granted in United States
20 November 2024 07:00
-
Interim results for the six months to 30 June 2024
18 September 2024 07:00
-
Holding(s) in Company
12 August 2024 13:28
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.